AR122819A1 - METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE - Google Patents

METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE

Info

Publication number
AR122819A1
AR122819A1 ARP210101838A ARP210101838A AR122819A1 AR 122819 A1 AR122819 A1 AR 122819A1 AR P210101838 A ARP210101838 A AR P210101838A AR P210101838 A ARP210101838 A AR P210101838A AR 122819 A1 AR122819 A1 AR 122819A1
Authority
AR
Argentina
Prior art keywords
irf5
methods
antisense oligonucleotide
safe administration
administration
Prior art date
Application number
ARP210101838A
Other languages
Spanish (es)
Inventor
Damayanthi Devineni
Bart Frederick
Cathye Shu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR122819A1 publication Critical patent/AR122819A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los métodos para tratar a un sujeto humano que tiene una enfermedad asociada con el factor regulador de interferón 5 (IRF5) comprenden administrar al sujeto un oligómero antisentido a un ácido nucleico de IRF 5.Methods of treating a human subject having an interferon regulatory factor 5 (IRF5) associated disease comprise administering to the subject an antisense oligomer to an IRF 5 nucleic acid.

ARP210101838A 2020-07-01 2021-06-30 METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE AR122819A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063047169P 2020-07-01 2020-07-01

Publications (1)

Publication Number Publication Date
AR122819A1 true AR122819A1 (en) 2022-10-05

Family

ID=83835086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101838A AR122819A1 (en) 2020-07-01 2021-06-30 METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE

Country Status (1)

Country Link
AR (1) AR122819A1 (en)

Similar Documents

Publication Publication Date Title
CL2021000435A1 (en) Methods for treating Fabry disease in patients with a mutation in the gla gene
CL2020002401A1 (en) Arni compositions of 17 b-hydroxysteroid dehydrogenases type 13 (hsd17b13) and methods of use thereof.
CL2020002352A1 (en) Cyclopentane-based sting modulators (interferon gene stimulator)
PE20142362A1 (en) IARN AGENTS, COMPOSITIONS AND METHODS OF USE OF THE SAME TO TREAT TRANSTIRETIN-ASSOCIATED DISEASES (TTR)
UY25869A1 (en) CCR5 MODULATORS, PHARMACEUTICAL FORMULATIONS, PROCEDURES AND THEIR USES.
CL2020002512A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors.
AR034746A1 (en) COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
ES2127203T3 (en) VACCINES AND METHODS FOR ITS PRODUCTION.
CL2021003280A1 (en) Methods of treating Fabry disease in patients who have renal failure
BR112022002202A2 (en) Methods of treating Fabry disease in patients having a mutation in the gla gene
CL2022001503A1 (en) Human chromosome 9 open reading frame 72 (c9orf72) arni agents, compositions
CO2021000914A2 (en) Recombinant adeno-associated virus products and methods for the treatment of girdle muscular dystrophy 2a
AR112166A1 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B
ES2187568T3 (en) LIVE VACCINE FOR THE TREATMENT OF TUMOR DISEASES.
CO2022003321A2 (en) Sting modulators (interferon gene stimulator)
CL2021003474A1 (en) Pharmaceutical product for enzyme therapy for the treatment of homocystinuria
CO6361950A2 (en) COMPOSITIONS, VACCINES AND METHODS OF THE VIRUS OF HERPES OF BOVINE LIVES -1
AR119033A1 (en) METHODS FOR TREATING VIRUS-ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS
ES2563068T3 (en) Multiple sclerosis (MS) treatment with Campath-1H
CL2022000790A1 (en) Method to treat hiv with cabotegravir and rilpivirine
AR122819A1 (en) METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
UY39304A (en) METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
AR039895A1 (en) COMPOSITION THAT INCLUDES A VITAMIN, A METAL SALT AND AN INSULIN OR A HORMONE OF THE GROWTH AND USE OF SUCH COMPONENTS TO PREPARE IT
AR095416A1 (en) TREATMENT WITH CUTIRSEN THAT PRESENTS A REDUCED TOXICITY
AR122341A1 (en) METHOD FOR THE TREATMENT OF CANCER USING ARTIFICIAL ADJUVANT CELL (AAVC)

Legal Events

Date Code Title Description
FB Suspension of granting procedure